Drug intelligence / Profile preview

HS-20090

Development stage: Phase 1
Lead developer: Hansoh Pharmaceutical Group
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

HS-20090 is a human IgG2 monoclonal antibody with affinity and specificity for human RANK ligand (RANKL). It is being developed by Jiangsu Hansoh Pharmaceutical as a biosimilar to Denosumab (Xgeva®). The drug works by inhibiting RANKL, which plays a crucial role in bone metabolism. HS-20090 is primarily being developed for the prevention or delay of bone-related events in patients with bone metastases from solid tumors. Clinical studies have shown that HS-20090 is highly similar to Xgeva® in terms of pharmacokinetics, pharmacodynamics, safety profiles, and immunogenicity in healthy Chinese subjects.

Other names: Recombinant human anti-RANKL monoclonal antibody

Targets

RANKL (Receptor Activator for Nuclear Factor-kappa B Ligand)

Beyond the preview

Go deeper on HS-20090.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HS-20090.

Explore the full profile